BCYC vs. NUVB, NRIX, ANAB, MLYS, DNTH, PAHC, WVE, CVAC, SLN, and SVRA
Should you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Nuvation Bio (NUVB), Nurix Therapeutics (NRIX), AnaptysBio (ANAB), Mineralys Therapeutics (MLYS), Dianthus Therapeutics (DNTH), Phibro Animal Health (PAHC), Wave Life Sciences (WVE), CureVac (CVAC), Silence Therapeutics (SLN), and Savara (SVRA). These companies are all part of the "pharmaceutical preparations" industry.
Bicycle Therapeutics (NASDAQ:BCYC) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
Bicycle Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
In the previous week, Nuvation Bio had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for Nuvation Bio and 6 mentions for Bicycle Therapeutics. Nuvation Bio's average media sentiment score of 0.93 beat Bicycle Therapeutics' score of 0.93 indicating that Nuvation Bio is being referred to more favorably in the news media.
Nuvation Bio has lower revenue, but higher earnings than Bicycle Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Bicycle Therapeutics presently has a consensus price target of $46.86, suggesting a potential upside of 111.26%. Nuvation Bio has a consensus price target of $6.60, suggesting a potential upside of 93.55%. Given Bicycle Therapeutics' higher possible upside, equities research analysts clearly believe Bicycle Therapeutics is more favorable than Nuvation Bio.
Nuvation Bio has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -404.14%. Nuvation Bio's return on equity of -12.21% beat Bicycle Therapeutics' return on equity.
Bicycle Therapeutics received 89 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 72.09% of users gave Nuvation Bio an outperform vote while only 68.57% of users gave Bicycle Therapeutics an outperform vote.
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 36.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Nuvation Bio beats Bicycle Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Bicycle Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bicycle Therapeutics Competitors List
Related Companies and Tools
